Comparative Pharmacology
Head-to-head clinical analysis: ALCAFTADINE versus BEPOTASTINE BESILATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALCAFTADINE versus BEPOTASTINE BESILATE.
ALCAFTADINE vs BEPOTASTINE BESILATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective histamine H1 receptor antagonist; inhibits histamine release from mast cells and reduces ocular itch associated with allergic conjunctivitis.
Bepotastine besilate is a selective histamine H1 receptor antagonist that inhibits histamine release from mast cells and reduces eosinophil chemotaxis, thereby suppressing allergic inflammatory responses.
1 drop of 0.25% ophthalmic solution in each affected eye twice daily.
2 mg/mL ophthalmic solution: 1 drop in each affected eye twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–3 h) after topical ocular administration, appropriate for twice-daily dosing.
Clinical Note
moderateAlcaftadine + Betahistine
"The therapeutic efficacy of Betahistine can be decreased when used in combination with Alcaftadine."
Clinical Note
moderateAmphetamine + Alcaftadine
"Amphetamine may decrease the sedative activities of Alcaftadine."
Clinical Note
moderateDiethylpropion + Alcaftadine
"Diethylpropion may decrease the sedative activities of Alcaftadine."
Clinical Note
moderatePhentermine + Alcaftadine
Terminal elimination half-life is approximately 9-10 hours in healthy adults, allowing twice-daily dosing for allergic conjunctivitis.
Primarily renal (approximately 50% unchanged), with the remainder as metabolites; negligible biliary/fecal elimination.
Primarily renal excretion as unchanged drug (~75-80% of dose) with minor fecal elimination (~10-15%).
Category C
Category C
Ophthalmic Antihistamine
Ophthalmic Antihistamine
"Phentermine may decrease the sedative activities of Alcaftadine."